Perception Mapping
Opportunity analysis for current offerings: Big & Mid pharma
Current Customer analysis
Analysis by segments
Analysis by geographical locations of clients
Pipeline Customer analysis
Analysis by segments
Analysis by geographical locations of clients
Expected sales value from the customers in pipeline
White space analysis of the Big & Mid pharma companies
Opportunity analysis for current offerings: Small pharma
Segmenting and Targeting of companies
Scoring methodology for companies
White space analysis of the Small pharma companies
More than 20% of the total clients in Big pharma accounted for over 40% of the total subscription revenues in 2011 The subscription revenues grew at a CAGR of 34.65% while the number of clients declined at a CAGR of 5.79% during 2008-11.
About 75% of the total clients located in U.S. & Europe accounted for over 80% subscription revenues in 2011
The clients in Europe and U.S. accounted for about 55% and 25% of the total subscription revenues, respectively during 2008-11
The sales value and probability adjusted sales value from the Big Pharma customers in pipeline is expected to be about $30K and $18K, respectively in 2012
The sales value and probability adjusted sales value from the U.S. customers in pipeline is expected to be about $53K and $29K, respectively in 2012
Total white space opportunity among big and mid-sized